First-line treatment study for advanced small cell esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests JS001 plus TP as a first treatment for people with advanced or unresectable small cell esophageal cancer. It aims to see how well this combination controls the cancer and improves outcomes compared with starting treatment with standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old.
- Your cancer is confirmed as small cell cancer of the esophagus, and it can’t be removed by surgery or has spread/returned.
- You have not had any “systemic” anti-cancer treatment before (treatments that travel through the body).
- If you previously had chemo with surgery or chemo with radiation for a curative attempt, the cancer must have come back or spread more than 6 months after that treatment ended.
- You must have at least one measurable tumor spot and be fit for treatment based on standard blood test and heart/lung status (ECOG 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a personalized treatment plan based on specific markers from your tumor can work better than standard chemotherapy for advanced esophageal cancer that has spread. It aims to find the best first treatment for your cancer type.
This trial tests a combination of a new form of chemotherapy (docetaxel albumin-bound), an immunotherapy (SG001), and standard chemotherapy (cisplatin) plus radiation for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
This trial tests a new combination of drugs (SYS6010, enlonstobart, and chemotherapy) as a first treatment for people with advanced esophageal cancer that has not spread elsewhere. It aims to find a more effective option for patients who have not received prior therapy for their advanced disease.
This trial tests a combination of immunotherapy (adebrelimab) and two chemotherapy drugs before surgery for patients with advanced but removable esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
Hear when a new Esophageal Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.